Medpace Holdings, Inc. (MEDP)
Medpace Holdings, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Cincinnati, OH, US. The stock last traded at $617.34, up 3.68% on the session, giving a market capitalisation of $17.23B. On trailing twelve-month figures it carries a trailing P/E of 35.50, a net margin of 17.7%. Its beta of 1.15 implies it has historically moved more than the broad market.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Medpace Holdings, Inc. is most often compared with the following Healthcare names: